This week, nine Biotechnology stocks are improving their overall ratings on . Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Isis Pharmaceuticals (NASDAQ:) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Isis Pharmaceuticals discovers and develops novel human therapeutic compounds. In Portfolio Grader’s specific subcategory of Earnings Momentum, ISIS also gets an A. .
Sarepta Therapeutics Inc (NASDAQ:) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. Shares of SRPT have increased 174.4% over the past month, better than the 4.5% increase the Nasdaq has seen over the same period of time. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. .
Neurocrine Biosciences (NASDAQ:) is seeing ratings go up from a C last week to a B this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. .
The rating of Medivation (NASDAQ:) moves up this week, rising from a B to an A. Medivation acquires, develops, and sells or partners biomedical technologies in the early development stage of the research and development process. Since last month, MDVN shares are up 2%. .
Threshold Pharmaceuticals (NASDAQ:) boosts its rating from a B to an A this week. Threshold Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as novel treatments for patients living with cancer. Wall Street seems to agree with the upgrade and has propelled the stock up 0.9% over the past month.
.
Lexicon Pharmaceuticals (NASDAQ:) shows solid improvement this week. The company’s rating rises from a C to a B. Lexicon Pharmaceuticals researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. .
Maxygen‘s (NASDAQ:) ratings are looking better this week, moving up to a B from last week’s C. Maxygen is a biopharmaceutical company which researches and develops protein drugs. The stock currently has a trailing PE Ratio of 3.6. MAXY shares inched up 1.8% over the past month. .
Celsion (NASDAQ:) improves from a C to a B rating this week. Celsion is an innovative oncology drug development company focused on improving treatment for those suffering with aggressive and difficult to treat forms of cancer. Shares of the stock have been trading at an exceptionally rapid pace, up 420.4% from the week prior. Over the past month, CLSN shares are up 14.8%. .
Pluristem Therapeutics‘s (NASDAQ:) gets a higher grade this week, advancing from a C last week to a B. Pluristem Therapeutics develops Messenchymal stem cell production technology and commercializes cell therapy products. Investors have pushed the stock price up 54.3% over the past month. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. .
Louis Navellier’s proprietary stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool .
